anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
RATIONALE AND OBJECTIVE: Stroke-associated pneumonia (SAP) often appears as a complication following intracerebral hemorrhage (ICH), leading to poor prognosis and increased mortality rates. Previous studies have typically developed prediction models based on clinical data alone, without considering that ICH patients often undergo CT scans immediately upon admission. As a result, these models are subjective and lack real-time applicability, with low accuracy that does not meet clinical needs. Therefore, there is an urgent need for a quick and reliable model to timely predict SAP.
METHODS: In this retrospective study, we developed an image-based model (DeepSAP) using brain CT scans from 244 ICH patients to classify the presence and severity of SAP. First, DeepSAP employs MRI-template-based image registration technology to eliminate structural differences between samples, achieving statistical quantification and spatial standardization of cerebral hemorrhage. Subsequently, the processed images and filtered clinical data were simultaneously input into a deep-learning neural network for training and analysis. The model was tested on a test set to evaluate diagnostic performance, including accuracy, specificity, and sensitivity.
RESULTS: Brain CT scans from 244 ICH patients (mean age, 60.24; 66 female) were divided into a training set (n = 170) and a test set (n = 74). The cohort included 143 SAP patients, accounting for 58.6% of the total, with 66 cases classified as moderate or above, representing 27% of the total. Experimental results showed an AUC of 0.93, an accuracy of 0.84, a sensitivity of 0.79, and a precision of 0.95 for classifying the presence of SAP. In comparison, the model relying solely on clinical data showed an AUC of only 0.76, while the radiomics method had an AUC of 0.74. Additionally, DeepSAP achieved an optimal AUC of 0.84 for the SAP grading task.
CONCLUSION: DeepSAP's accuracy in predicting SAP stems from its spatial normalization and statistical quantification of the ICH region. DeepSAP is expected to be an effective tool for predicting and grading SAP in clinic.
All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
Group B patients will receive tab tamoxifen 10 mg twice a day and cap. vit E 400mg once a day for total of six months.
Methods, computer systems and computer readable media cause an infusion pump to provide a line check validation. A medical device that needs a line check validation is provided to a clinician via a graphical user interface. A selection of the medical device that needs the line check validation is received via the graphical user interface. The line check validation is automatically performed based on the selection. In aspects, the line check validation comprises establishing a first connection between a computing device associated with the graphical user interface and a second computing device associated with a patient. Further, the line check validation comprises establishing a second connection between the computing device and the medical device. As such, the medical device for the patient is automatically validated based on the first connection and the second connection.
In the initial phase of this study, HIV-infected patients with CD4 counts between 200 and 500 were randomized to receive either IL-2 alone by continuous IV infusion for 5 days every 8 weeks, IL-2 plus anti-TNF antibody, or IL-2 plus thalidomide. The primary endpoints of this study are safety and tolerability of the IL-2/TNF inhibitor combination. Secondary endpoints will include changes in CD4 counts, frequency and severity of IL-2 related side effects, changes in serum TNF levels, and plasma viral load changes. The study period is one year, with an optional extension period to follow. Enrollment was for up to forty-five IL-2-naive patients.

In the amended phase of this study, up to 60 patients with HIV infection and CD4 counts equal to or greater than 350 will be studied to determine the ability of prednisone to ameliorate IL-2 related toxicity. Patients will be randomized to one of four groups: IL-2 alone; IL-2 plus prednisone; prednisone alone; no treatment. All four groups will be treated with a combination regimen of antiretrovirals to include at least one protease inhibitor. IL-2 will be dosed SQ at a starting dosage of 7.5 mlU bid x 5 days every 8 weeks, and prednisone (or placebo) will be dosed at 0.5 mg/kg/day during IL-2 cycles. Primary endpoints are frequency of IL-2 associated fatigue and fever, CD4 count changes, and viral load changes. Secondary endpoints include frequency of other IL-2 side effects, concomitant medication use, steroid associated side effects, cytokine changes during IL-2, and IL-2 total exposure in the IL-2 plus steroid vs. IL-2 plus placebo arms. The study period is one year with an optional extension period to follow.
Despite the existence of numerous, well-established evidence-based practices (EBPs) for mental disorders, it has been difficult to disseminate these practices in community settings. Exposure therapy for anxiety disorders represents one of the most glaring examples of this research-to-practice gap. Just as patients are anxious about approaching their fears, therapists are often reluctant to use exposure therapy due to their own anxious beliefs that it may be dangerous and/or intolerable for patients, even after receiving specialized exposure training. Emerging training research suggests the inclusion of targeted behavioral strategies (i.e., role play, self-exposure) can reduce anxious beliefs above and beyond standard didactic training sessions. By leveraging the same behavior change principles that reduce patient anxiety (i.e., exposure), behavioral strategies can be tailored to target therapists' anxious beliefs about the treatment (i.e., conduct training as "exposure to exposure"). Unfortunately, current experiential training tasks have failed to closely replicate commonly feared clinical contexts, and as a result lack the necessary potency to potentially overcome therapist-level barriers for uptake and quality treatment delivery following training. Virtual reality (VR) has demonstrated utility as a potent and cost-effective approach for delivering exposure. We plan to investigate the application of VR as a tailored training tool (i.e., virtual "exposure to exposure" for therapists) capable of enhancing the quantity and quality of experiential learning that is lacking in current exposure training initiatives. This study will test the implementation of a VR training program on both a low-immersion (i.e., mobile device) and high-immersion (i.e., head mounted display) platform to assess which platform provides the ideal balance of immersion, usability, target engagement, and scalability. The study involves a clinical training trial to establish target engagement. Usability and target engagement information from this pilot trial will support a Phase II project aimed at building out and broadly disseminating the VR-enhanced training approach.
Locally advanced pelvic malignancies pose numerous technical difficulties to oncological surgeons, particularly where extended resections are performed. The repair of skin and soft tissue defects after radical resections are among the most challenging. Complications related to wound healing are among the most commonly encountered. They can increase rates of infection in the short-term and often become chronic and difficult to treat. This is particularly relevant in the context of pelvic exenteration, where a larger dead space confers a greater risk of deep perineal wound infection and prior (chemo)radiotherapy impairs tissue quality with suboptimal healing. Primary closure may also lead to higher tension closure where there is a bigger defect, further compounding risk. The first meta-analysis comparing primary closure to flap closure noted a two-fold increased risk of overall wound complications with primary closure (1).

With increasingly extensive procedures being carried out in dedicated centres over recent decades, the use of flap reconstruction for closure of pelvic oncological defects has increased significantly. Perineal reconstruction has been shown to decrease the incidence the wound of break-down as well as the need for a secondary repair of dehiscence (2). More importantly, these complications have been shown to be decreasing over time, suggesting improved techniques and/or better perioperative care. However, this is countered by an increase in the incidence of overall minor complications and the possibility of flap failure necessitating a return to theatre. Flap formation is a morbid procedure in its own right and can involve more intensive nursing care and restrict a patient's mobility after pelvic exenteration, further predisposing to post-operative complications and increasing length-of-stay.

The Vertical Rectus Abdominis Muscle (VRAM) flap remains one of the most commonly used and is considered by some to be the gold standard. However, a wide variety of methods have been proposed but exactly how often each is employed and with what outcomes remains largely unknown and is of great interest to surgeons involved in pelvic reconstruction. This review sought to assess the preferred methods for perineal reconstruction following pelvic exenteration by retrospectively assessing the outcomes associated with each at an international, multi-centre level.
Participants will be only asked to take conventional follow-ups at 1-, 3-, and 6-month post-operative. During these follow-ups, they will be asked to score VAS based on general pain state, and take questionnaires including EQ-5D-5L, PSQI, PGIC, CGI-I.
FIELD: medicinal genetics, medicine, oncology. SUBSTANCE: invention relates to the cellular line able to express molecules inhibiting the growth of tumor in the central nervous system being this cellular line is encapsulated into immunoisolating alginate gel. The encapsulated cellular line provides a novel approach for treatment of tumors that are localized in the central nervous system, such as the brain tumors. Invention provides expanding assortment of genetic agents used for treatment of brain tumors. EFFECT: valuable medicinal properties of agent. 15 cl, 1 tbl, 7 dwg
<P>PROBLEM TO BE SOLVED: To display cautionary information in a patient worklist so that it can be easily viewed.  <P>SOLUTION: An apparatus displaying a patient worklist (202) is configured to store patient information including cautionary information (304) and scheduled medical procedures in a memory and further configured to display the patient information on a display screen in a worklist of patient listings (206) for individual patients. The displayed patient information includes scheduled medical procedures for each patient and a visual cautionary indication in a consistent position relative to each patient in the worklist for whom cautionary information is stored. The apparatus is also configured to open a preview pane (302) on the display screen entirely within the viewing area of the display screen when the visual cautionary indication is selected by the pointing device. The preview pane contains cautionary details associated with the corresponding patient for the selected visual cautionary indication.  <P>COPYRIGHT: (C)2007,JPO&INPIT
ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
All participants will receive conventional physiotherapy for half an hour thrice weekly for six weeks. Conventional physiotherapy will be followed by a 15 min rest period, then the HIIT on a semi-recumbent cycle SOLE R92 (HIIT-RCE) will be performed.Each HIIT-RCE session will be preceded by 3-min of unloaded cycling as a warm-up and ended with 3-min of stretching. The HIIT-RCE procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload for weeks 1-2 (4 repetitions for 20 min) and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (6 repetitions). The training intensity will progress similarly by 5% peak work rate two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5. The cycle frequency will be at least 50 rpm.
The utility model relates to broad-spectrum antiseptic eye drops, in particular to broad-spectrum antiseptic eye drops with silver nanoparticles, which finding application in the field of medicine and in particular in ophthalmology. According to the utility model, the broad-spectrum antiseptic eye drops with silver nanoparticles, represent a colloid solution with a composition of silver nanoparticles chemically pure with sizes below 100 nm in a ratio of 20 mg - 40 mg of silver nanoparticles per litre of sterile double-distilled water, i.e. colloid solution with a composition of 2 - 4% silver nanoparticles in sterile double-distilled water. With application as intraocular broad-spectrum antiseptic eye drops with silver nanoparticles, they represent a colloid solution with a composition of silver nanoparticles chemically pure with sizes below 3 nm in a ratio of 20 mg - 40 mg of silver nanoparticles per litre of sterile double-distilled water, i.e. colloid solution with a composition of 2 - 4% silver nanoparticles in sterile double-distilled water. Broad-spectrum antiseptic eye drops with silver nanoparticles can be a hydrolat with a composition of silver nanoparticles - chemically pure with sizes below 100 nm in a ratio of 20 mg - 40 mg of silver nanoparticles in one litre of sterile distilled water /hydrolat/, i.e. they are a hydrolat with a composition of 2 - 4% silver nanoparticles in residual sterile distilled water /hydrolat/, obtained from the distillation of herbs, plants, fruits and others. With application also as intraocular broad-spectrum antiseptic eye drops with silver nanoparticles, they represents a hydrolat with a composition of silver nanoparticles - chemically pure with sizes below 3 nm in a ratio of 40 mg of silver nanoparticles in one litre of sterile distilled water /hydrolat/, i.e. they are a hydrolat with a composition of 4% silver nanoparticles in residual sterile distilled water, obtained from the distillation of herbs, plants and fruits, etc. Silver nanoparticles with a size of and below 3 nm can cross all eye barriers. Broad-spectrum antiseptic eye drops with silver nanoparticles have anti-inflammatory and anti-allergic effects. In the combination of silver nanoparticles in a hydrolat of herbs, plants and fruits they have an additive effect.
Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
Participants will be administered one dose of a 25mg capsule of psilocybin. This will be administered one time.
G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (\>=5\*10\^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
A patient group with 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis and who underwent a core needle biopsy again. A total thyroidectomy was performed in 88 of these patients. Surgical pathology results, core needle results and TIRADS scores were compared.
In children aged 1 to 3 years without heart disease, clinical observation suggests that an overdose of digoxin of 6 to 10 mg was the dose resulting in death in half of the patients. If more than 10 mg of digoxin was ingested by a child aged 1 to 3 years without heart disease, the outcome was uniformly fatal when Fab fragment treatment was not given. Most manifestations of toxicity in children occur during or shortly after the loading phase with digoxin. The same arrhythmias or combination of arrhythmias that occur in adults can occur in pediatrics. Sinus tachycardia, supraventricular tachycardia, and rapid atrial fibrillation are seen less frequently in the pediatric population. Pediatric patients are more likely to present with an AV conduction disturbance or a sinus bradycardia. Any arrhythmia or alteration in cardiac conduction that develops in a child taking digoxin should be assumed to be caused by digoxin, until further evaluation proves otherwise. 

The frequent extracardiac manifestations similar to those seen in adults are gastrointestinal, CNS, and visual. However, nausea and vomiting are not frequent in infants and small children. 

In addition to the undesirable effects seen with recommended doses, weight loss in older age groups and failure to thrive in infants, abdominal pain due to mesenteric artery ischemia, drowsiness, and behavioral disturbances including psychotic manifestations have been reported in overdose.
Post cesarean scar defect (PCSD), refers the lower uterine segment form a reservoir-like pouch during healing process after transverse lower uterine segment cesarean section connected with uterine cavity. The pouch has a valve-like effect, obstructing blood drainage and accumulating blood in depression. These causes may lead to a variety of gynecological disturbances, secondary dysmenorrheal and infertility. Some patients can occur some serious obstetric complications, such as cesarean scar pregnancy and even the rupture of uterus during a subsequent pregnancy. At present, the causes and mechanisms of PCSD are not clear, diagnosis and treatment are not uniform. Surgical methods include abdominal surgery, laparoscopic surgery, transvaginal surgery, hysteroscopic surgery, hysteroscopic with laparoscopic surgery and so on. Hysteroscopic and transvaginal surgery to treating PCSD both are minimally invasive and feasible surgical approach. However, hysteroscopic surgery and transvaginal surgery have not been compared for correcting the uterine defect in patients with PCSD before.
Participants randomized to the intervention group will use the BP group using the iLet Bionic Pancreas System (BP) and continuous glucose monitoring (CGM) during the first 13-week of the study (RCT phase). After the RCT phase, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system.
Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
Obesity is a chronic disease characterized by increased body fat mass and adipose tissue dysfunction, the pathogenesis of which is based on a neurobiological regulatory disorder of energy homeostasis. The primary aim of medical obesity therapy is to reduce the pathologically increased body fat mass and thus prevent secondary diseases and improve comorbidities. In this sense, bariatric-metabolic surgery is currently the most effective obesity therapy. In addition, new agents, which are essentially based on GLP-1 receptor agonism, are making pharmacological therapy increasingly effective. It is important to note that both bariatric-metabolic surgery as well as the pharmacological obesity therapy have direct effects on the central nervous regulation of energy homeostasis and, in particular, hunger and appetite, and therefore represent pathogenetically causal therapies. In this overview, we aim to shed light on the aforementioned medical interventions for obesity therapy and place them in the context of a pathogenetic disease concept.
Multicomponent and multisectoral community-based interventions (CBIs) have proven potential in preventing overweight and obesity in children. Synthesizing evidence on the outcomes collected and reported in such CBIs is critical for the evidence of effectiveness and cost-effectiveness. This systematic review aimed to identify the range of outcomes and outcome measurement instruments collected and reported in multisectoral and multicomponent CBIs for obesity prevention in children. A systematic search updated an existing review and extended the search to 11 academic databases (2017-2023) and gray literature. Outcomes were classified into outcome domains, and common measurement instruments were summarized. Seventeen outcome domains from 140 unique outcomes were identified from 45 included interventions reported in 120 studies. The most frequently collected outcome domains included anthropometry and body composition (91% of included interventions), physical activity (84%), dietary intake (71%), environmental (71%), and sedentary behavior (62%). The most frequently collected outcomes from each of these domains included body mass index (89%), physical activity (73%), fruit and vegetable intake (58%), school environment (42%), and screen time (58%). Outcome measurement instruments varied, particularly for behavioral outcomes. Standardization of reported outcomes and measurement instruments is recommended to facilitate data harmonization and support quantifying broader benefits of CBIs for obesity prevention.
The invention belongs to the technical field of veterinary drugs and relates to a livestock antibacterial drug of broad spectrum antibiotic solution prepared by using cefquinome as a raw material. The cefquinome solution uses hexacyclic water as a carrier. The hexacyclic water prepared by refrigeration is filled in the cefquinome solution, so that the volume of water clusters is reduced and correspondingly the viscosity, surface tension and the like of water are reduced to reduce the diffusion resistance of the cefquinome and to promote drug release. The speed and amount of drug release of the cefquinome solution are improved. The hexacyclic water has high cellular affinity. The livestock cefquinome solution containing hexacyclic water is used for treating sensitive bacteria infection of livestock, obviously improves the treatment effect of the drug, and quickly promotes the restoration from diseases.